A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia
K Wiśniewski, B Puła - International Journal of Molecular Sciences, 2024 - mdpi.com
Bruton's Tyrosine Kinase (BTK) inhibitors have become one of the most vital drugs in the
therapy of chronic lymphocytic leukemia (CLL). Inactivation of BTK disrupts the B-cell …
therapy of chronic lymphocytic leukemia (CLL). Inactivation of BTK disrupts the B-cell …
Targeting the NTSR2/TrkB oncogenic pathway in chronic lymphocytic leukemia
L Ikhlef, M Yassine, B Chandouri, L Rivière, T Naves… - Scientific Reports, 2024 - nature.com
Current therapies that target the B-cell receptor pathway or the inhibition of anti-apoptotic
proteins do not prevent the progressive forms of chronic lymphocytic leukemia (CLL), have …
proteins do not prevent the progressive forms of chronic lymphocytic leukemia (CLL), have …
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax
L Scarfò - Hematology, 2022 - ashpublications.org
Patients with chronic lymphocytic leukemia (CLL) refractory to covalent BTK and BCL2
inhibitors have a new unmet clinical need. Standard treatment options are able to obtain …
inhibitors have a new unmet clinical need. Standard treatment options are able to obtain …
Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus‐based position paper from an ad hoc expert …
FR Mauro, A Tedeschi, M Varettoni, F Zaja… - Hematological …, 2024 - Wiley Online Library
Zanubrutinib has been approved for treating patients with different lymphoproliferative
disorders and now represents a significant breakthrough in treating relapsed/refractory and …
disorders and now represents a significant breakthrough in treating relapsed/refractory and …
[HTML][HTML] Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotype and phenotype in chronic lymphocytic leukemia
Bruton's tyrosine kinase (BTK) inhibitors are effective for the treatment of chronic lymphocytic
leukemia (CLL) due to BTK's role in B cell survival and proliferation. Treatment resistance is …
leukemia (CLL) due to BTK's role in B cell survival and proliferation. Treatment resistance is …
[HTML][HTML] Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL
We retrospectively analyzed 609 chronic lymphocytic leukemia (CLL) patients treated with
BTK inhibitors (BTKis) at Dana-Farber Cancer Institute from 2014 to 2022. Among them, 85 …
BTK inhibitors (BTKis) at Dana-Farber Cancer Institute from 2014 to 2022. Among them, 85 …
Clonal dynamics of Richter transformation in chronic lymphocytic leukemia
Clonal dynamics of Richter transformation in chronic lymphocytic leukemia Clonal dynamics of
Richter transformation in chronic lymphocytic leukemia Hematol Oncol. 2024 Jul;42(4):e3282 …
Richter transformation in chronic lymphocytic leukemia Hematol Oncol. 2024 Jul;42(4):e3282 …
Involvement of prohibitins in an oncogenic protein complex in Chronic Lymphocytic Leukemia
Abstract Prohibitins (PHB1 and PHB2) are highly conserved and ubiquitously expressed
proteins that are mainly localized in the mitochondria. They have been reported to have …
proteins that are mainly localized in the mitochondria. They have been reported to have …
Subclonal Evolution in Chronic Lymphocytic Leukemia: Dissecting Genetic Heterogeneity and Its Clinical Implications
GS Black - 2024 - search.proquest.com
Chronic lymphocytic leukemia (CLL) is characterized by an overaccumulation of
dysfunctional B cells and currently has no cure. It is the most prevalent subtype of leukemia …
dysfunctional B cells and currently has no cure. It is the most prevalent subtype of leukemia …
Investigating longitudinal evolution of liquid cancers using computational and mathematical models
ND Lee - 2022 - digital.lib.washington.edu
Cancer can result from a series of driver mutations, alterations in the genome sequence that
confer a fitness advantage to cells containing them, resulting in their net proliferation …
confer a fitness advantage to cells containing them, resulting in their net proliferation …